Aquestive Therapeutics, Inc. (AQST)
NASDAQ: AQST · IEX Real-Time Price · USD
4.500
+0.580 (14.80%)
At close: Apr 18, 2024, 4:00 PM
4.400
-0.100 (-2.22%)
Pre-market: Apr 19, 2024, 8:20 AM EDT

Aquestive Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Year 20232022202120202019201820172016
Net Income
-7.87-54.41-70.54-55.78-66.25-61.38-11.42-11.94
Depreciation & Amortization
1.352.392.963.442.913.243.83.89
Share-Based Compensation
2.694.386.826.587.0729.9400
Other Operating Activities
-2.5437.8227.780.3-3.9415.2110.97-2.46
Operating Cash Flow
-6.38-9.82-32.98-45.46-60.21-12.995.82-8.18
Capital Expenditures
-1-1.02-0.91-0.52-0.66-1.82-2.07-0.98
Change in Investments
00000001.17
Other Investing Activities
--1.5------
Investing Cash Flow
-1-2.52-0.91-0.52-0.66-1.82-2.070.19
Share Issuance / Repurchase
17.2613.6230.126.2239.3268.8300
Debt Issued / Paid
-13.27-2.03022.3413.11-4.7755.69
Other Financing Activities
-0.01-0-0.01-0.1-2.83-6.03-0.59-
Financing Cash Flow
3.9711.5930.1128.4649.658.044.415.69
Net Cash Flow
-3.4-0.75-3.78-17.52-11.2743.228.17-2.3
Free Cash Flow
-7.38-10.84-33.89-45.98-60.87-14.823.76-9.15
Free Cash Flow Margin
-14.58%-22.74%-66.67%-100.28%-115.71%-21.97%5.61%-17.67%
Free Cash Flow Per Share
-0.12-0.22-0.89-1.37-2.40-0.710.03-0.08
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).